LAUREN HARDY: Open Payments
NPI 1881009934 · SIKESTON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,760 in 92 payments from 19 companies in 2025. Trend: 2023 $1,475 · 2024 $1,168 · 2025 $1,760
Food & beverage: $1,760
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $485 |
| Amgen Inc. | 18 | $305 |
| Otsuka America Pharmaceutical, Inc. | 8 | $143 |
| AstraZeneca Pharmaceuticals LP | 4 | $136 |
| Lilly USA, LLC | 9 | $124 |
| Novo Nordisk Inc | 6 | $119 |
| Eisai Inc. | 4 | $104 |
| Dexcom, Inc. | 4 | $75 |
| Novartis Pharmaceuticals Corporation | 3 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $47 |
Products named: VRAYLAR, REPATHA, REXULTI, OTEZLA, MOUNJARO, Leqembi, BREZTRI, Dexcom G6 Transmitter.
Industry payments across MO — which companies pay providers there.
